You searched for Gout - Page 59 of 96

Abstract Number: 1630 • 2012 ACR/ARHP Annual Meeting
Genetic Variants of Serum Uric Acid and Gout: An Analysis of > 170,000 Individuals
Hyon Choi¹, Robert M. Plenge², Anna Köttgen³, Veronique Vitart⁴, Murielle Bochud⁵, Christian Gieger⁶, Mark Caulfield⁷, Marina Ciullo⁸, Eva Albrecht⁶, Alexander Teumer⁹, Gary Curhan¹⁰, Jan Krumsiek¹¹, Conall O'Seaghdha¹², Caroline Fox¹³ and The Global Urate Genetics Consortium (GUGC)¹⁴, ¹Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ²Division of Rheumatology, Immunology and Allergy and Division of Genetics, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ³Renal Division, Freiburg University Hospital, Freiburg, Germany, ⁴Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, United Kingdom, ⁵Institute of Social and Preventive Medicine (IUMSP), Lausanne University Hospital, Switzerland, ⁶German Research Center for Environmental Health, Neuherberg, Germany, ⁷William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ⁸Institute of Genetics and Biophysics, "A. Buzzati-Traverso", Italy, ⁹Interfaculty Institute for Genetics and Functional Genomics, Ernst-Moritz-Arndt- University Greifswald, Greifswald, Germany, ¹⁰German Research Center for Environmental Health, Harvard Medical School, Boston, MA, ¹¹Institute of Bioinformatics and Systems Biology, German Research Center for Environmental Health, Neuherberg, Germany, ¹²German Research Center for Environmental Health, NHLBI's Framingham Heart Study and Center for Population Studies,, Neuherberg, ¹³Institute of Genetics and Biophysics, NHLBI's Framingham Heart Study and Center for Population Studies, Framingham, MA, ¹⁴Section of Rheumatology and the Clinical Epidemiology Unit, Boston University of School of Medicine, Boston, MA
Background/Purpose: Gout is a common and excruciatingly painful inflammatory arthritis caused by hyperuricemia. In addition to various lifestyle risk factors, a substantial genetic predisposition to…
Abstract Number: 1633 • 2012 ACR/ARHP Annual Meeting
Ulodesine (BCX4208) Add-On Therapy to Allopurinol 300mg Lowers Hypoxanthine and Xanthine Plasma Levels in a Dose-Dependent Fashion: Results From a 12-Week Randomized Controlled Trial in Patients with Gout
Shanta Bantia¹, Leigh Harman², Cynthia Parker¹, Damon Papac³, Andreas Maetzel⁴, Brian Taubenheim⁴ and Alan S. Hollister⁴, ¹Discovery Biology, BioCryst Pharmaceuticals, Inc., Durham, NC, ²Bioanalytical Chemistry, BioCryst Pharmaceuticals, Inc., Durham, NC, ³Bioanalytical Sciences, Southern Research Institute, Birmingham, AL, ⁴Development, BioCryst Pharmaceuticals, Inc., Durham, NC
Background/Purpose: Ulodesine (BCX4208) is an oral, once-daily, purine nucleoside phosphorylase (PNP) inhibitor in clinical development as add-on therapy for the chronic management of hyperuricemia in…
Abstract Number: 1035 • 2012 ACR/ARHP Annual Meeting
Characterisation of New Bone Formation in Gout: A Quantitative Site-by-Site Analysis Using Plain Radiography and Computed Tomography
Nicola Dalbeth¹, Aaron Milligan², Barnaby Clark², Fiona M. McQueen³ and Anthony Doyle⁴, ¹Medicine, University of Auckland, Auckland, New Zealand, ²Department of Radiology, Auckland District Health Board, Auckland, New Zealand, ³Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand, ⁴University of Auckland, Auckland, New Zealand
Background/Purpose: Radiographic descriptions of gout have noted the tendency to hypertrophic bone changes. The aim of this study was to characterise the features of…
Abstract Number: 813 • 2012 ACR/ARHP Annual Meeting
Rilonacept for Gout Flare Prophylaxis in Patients with Chronic Kidney Disease: Analysis of 3 Clinical Trials
Robert Terkeltaub¹, Robert R. Evans², Steven P. Weinstein³, Richard Wu⁴ and H. Ralph Schumacher⁵, ¹Medicine-Rheumatology, VA Medical Ctr/University of California San Diego, San Diego, CA, ²Clinical Sciences, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ³Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ⁴BioStatistics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁵Department of Medicine, University of Pennsylvania and VA Medical Center, Philadelphia, PA
Background/Purpose: Gout flare (GF) prophylaxis in patients (pts) with chronic kidney disease (CKD; estimated glomerular filtration rate [eGFR]
Abstract Number: 814 • 2012 ACR/ARHP Annual Meeting
Familial Aggregation and Heritability of Gout in Taiwan: A Nationwide Population Study
Chang-Fu Kuo¹, Matthew J. Grainge², Lai-Chu See³, Kuang-Hui Yu⁴, Shue-Fen Luo⁴, Ana M. Valdes⁵, Weiya Zhang¹ and Michael Doherty⁶, ¹Academic Rheumatology, School of Clinical Sciences, University of Nottingham, Nottingham, United Kingdom, ²Division of Epidemiology and Public Health, School of Community Health Sciences,, University of Nottingham, Nottingham, United Kingdom, ³Department of Public Health, College of Medicine, Chang Gung University, Chang Gung University, Taoyuan, Taiwan, ⁴Division of Rheumatology, Immunology and Allergy, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁵Dept of Twin Research and Genetic Epidemiology, St. Thomas' Hospital, King's College London, London, United Kingdom, ⁶Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom
Background/Purpose: Gout has long been recognised to cluster within families. However, formal evidence for familial aggregation is scant and discordant and the magnitude of any…
Abstract Number: 816 • 2012 ACR/ARHP Annual Meeting
Glomerular Filtration Rate, Chronic Kidney Disease and Incidence of Physician Diagnosed Gout
Eswar Krishnan, Medicine, Standford University, Palo Alto, CA
Background/Purpose: The kidney is the major organ of urate excretion in humans. Yet, there are few studies that assess whether reduced glomerular filtration and/or kidney…
Abstract Number: 817 • 2012 ACR/ARHP Annual Meeting
Feasibility of Using a Pharnacist-Based Gout Management Clinic to Improve Serum Uric Acid in Gout Patients an a Large Prepaid Health Plan
Robert D. Goldfien¹, Michele S. Ng², Goldie M. Yip², Alice Hwe², Alice Pressman³ and Andy L. Avins³, ¹Kaiser Permanente, Richmond, CA, ²Pharmacy, Kaiser Permanente, Oakland, CA, ³Division of Research, Kaiser Permanente, Oakland, CA
Background/Purpose: Effective treatment for recurrent gout has been hampered by a number of problems including outdated treatment approaches, a failure to treat to target, and…
Abstract Number: 818 • 2012 ACR/ARHP Annual Meeting
Levotofisopam Has Uricosuric Activity and Reduces Serum Urate Levels in Patients with Gout
Robert J. Noveck¹, Zongyao Wang¹, Ann Forsthoefel¹, Kristina Sigmon², Pauliana C. Hall³, John C. Keogh⁴ and John S. Sundy², ¹Duke Clinical Research Unit, Duke University Medical Center, Durham, NC, ²Duke Clinical Research Institute, Duke University Medical Center, Durham, NC, ³PCH Integrated Regulatory Services, Inc., Laguna Niguel, CA, ⁴Keogh Medical Writing, Philadelphia, PA
Background/Purpose: The investigational new drug levotofisopam is the S-enantiomer of racemic tofisopam, a 2,3-benzodiazepine derivative approved in over 20 countries outside the US for treatment…
Abstract Number: 741 • 2012 ACR/ARHP Annual Meeting
Increased Risk of Recurrent Gout Attacks During Hospitalization
Yuqing Zhang¹, Clara Chen², Hyon K. Choi³, Christine E. Chaisson², David J. Hunter⁴ and Tuhina Neogi⁵, ¹Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ²Boston University School of Public Health, Boston, MA, ³Section of Rheumatology and the Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ⁴Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, ⁵Clinical Epidemiology, Boston Univ Schl of Med, Boston, MA
Background/Purpose: While anecdotal evidence suggests that risk of recurrent gout attack increases during hospitalization and gout is one of the most common reasons for in-patient…
Abstract Number: 743 • 2012 ACR/ARHP Annual Meeting
Anemia and the Onset of Gout in a Population-Based Cohort of Adults: Atherosclerosis Risk in Communities Study
Mara McAdams DeMarco¹, Janet W. Maynard², Josef Coresh¹ and Alan N. Baer³, ¹Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²Rheum/Mason F Lord Bldg/CtrTow, Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: There is a growing prevalence of gout in the US and worldwide. Gout is a recognized risk factor for cardiovascular disease (CVD). It is…
Abstract Number: 167 • 2012 ACR/ARHP Annual Meeting
Serum Uric Acid Control and Risk of Flare According to Different Cut-Offs in Patients with Gout: Longitudinal Analysis From the King Study of the Italian Society for Rheumatology
Maria Manara¹, Carlo Alberto Scirè¹, Marco A. Cimmino², Marcello Govoni³, Fausto Salaffi⁴, Greta Carrara¹, Carlomaurizio Montecucco⁵, Marco Matucci-Cerinic⁶, Giovanni Minisola⁷ and Kick-off of the Italina Network for Gout (KING) Study Group⁸, ¹Epidemiology Unit -Italian Society for Rheumatology, Milano, Italy, ²Rheumatology - Department of Internal Medicine - University of Genoa, Genova, Italy, ³Clinical and Experimental Medicine, Section of Rheumatology, University of Ferrara, Ferrara, Italy, ⁴Rheumatology Unit - Polytechnic University of the Marche, Jesi, Italy, ⁵Division of Rheumatology - University of Pavia School of Medicine, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, ⁶Department of Biomedicine & Division of Rheumatology AOUC - University of Florence, Florence, Italy, ⁷Rheumatology Unit - San Camillo Forlanini Hospital, Rome, Italy, ⁸Italian Society for Rheumatology, SIR, Italy
Background/Purpose: the therapeutic goal of the management of gout is to promote crystal dissolution and prevent crystal formation. For this reason national and international guidelines…
Abstract Number: 169 • 2012 ACR/ARHP Annual Meeting
Post-Marketing Safety Surveillance Data Reveals Patterns of Use for Pegloticase in Refractory Chronic Gout
Kenneth M. Bahrt¹, Anthony E. Yeo², Tina L. Howson³ and Faith D. Ottery¹, ¹Medical Affairs, Savient Pharmaceuticals, Inc., East Brunswick, NJ, ²Savient Pharmaceuticals, Inc., East Brunswick, NJ, ³Savient Pharmaceuticals, Inc., Bridgewater, NJ
Background/Purpose: Pegloticase is a recombinant modified mammalian uricase conjugated to mPEG which was approved in the US in 2010 for treating hyperuricemia in patients with…
Abstract Number: 147 • 2012 ACR/ARHP Annual Meeting
Improvements in Long-Term Health-Related Quality of Life in Chronic Gout Patients Refractory to Conventional Therapies Treated with Pegloticase: Results From Responder Cohort
Dinesh Khanna¹, Puja Khanna² and Faith D. Ottery³, ¹Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²Division of Rheumatology/Dept. of Internal Medicine, University of Michigan Medical Center, Ann Arbor, MI, ³Medical Affairs, Savient Pharmaceuticals, Inc., East Brunswick, NJ
Background/Purpose: In replicate, 6-month, randomized, placebo-controlled Phase 3 clinical trials a subgroup of patients with treatment-refractory chronic gout (RCG) who received pegloticase infusions (8 mg)…
Abstract Number: 148 • 2012 ACR/ARHP Annual Meeting
Towards a Preliminary Definition of Remission From Gout
William Taylor¹, Nicola Dalbeth², Jasvinder A. Singh³, Kenneth G. Saag⁴ and H. R. Schumacher⁵, ¹University of Otago, Wellington, New Zealand, ²Medicine, University of Auckland, Auckland, New Zealand, ³Department of Medicine, University of Alabama, Tuscaloosa, AL, ⁴Div Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, ⁵Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA
Background/Purpose: There is currently no agreed criterion for remission in chronic gout. The aim of this study was to develop a preliminary definition for remission…
Abstract Number: 149 • 2012 ACR/ARHP Annual Meeting
Natural Language Processing in the Evaluation of Gout Quality Indicators
Gail S. Kerr¹, J. Steuart Richards², Carl A. Nunziato³, Olga V. Patterson⁴, Scott L. DuVall⁵, David D. Maron⁶ and Richard L. Amdur⁷, ¹Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ²Rheumatology, Washington DC VA and Georgetown University, Washington, DC, ³Rheumatology, Washington DC VA and Howard University, Washington, DC, ⁴VA Salt Lake City Health Care System and University of Utah School of Medicine, UT, ⁵VA Salt Lake City Health Care System and University of Utah School of Medicine, Salt Lake City, UT, ⁶Research Department, Washington DC VA Medical Center, Washington, DC, ⁷Washington DC VA and Georgetown Unviversity, Washington, DC
Background/Purpose: Gout is a common inflammatory arthritis with significant impact on both patients and health care systems. Despite ACR/EULAR management guidelines and gout quality indicators…

Genetic Variants of Serum Uric Acid and Gout: An Analysis of > 170,000 Individuals

Ulodesine (BCX4208) Add-On Therapy to Allopurinol 300mg Lowers Hypoxanthine and Xanthine Plasma Levels in a Dose-Dependent Fashion: Results From a 12-Week Randomized Controlled Trial in Patients with Gout

Characterisation of New Bone Formation in Gout: A Quantitative Site-by-Site Analysis Using Plain Radiography and Computed Tomography

Rilonacept for Gout Flare Prophylaxis in Patients with Chronic Kidney Disease: Analysis of 3 Clinical Trials

Familial Aggregation and Heritability of Gout in Taiwan: A Nationwide Population Study

Glomerular Filtration Rate, Chronic Kidney Disease and Incidence of Physician Diagnosed Gout

Feasibility of Using a Pharnacist-Based Gout Management Clinic to Improve Serum Uric Acid in Gout Patients an a Large Prepaid Health Plan

Levotofisopam Has Uricosuric Activity and Reduces Serum Urate Levels in Patients with Gout

Increased Risk of Recurrent Gout Attacks During Hospitalization

Anemia and the Onset of Gout in a Population-Based Cohort of Adults: Atherosclerosis Risk in Communities Study

Serum Uric Acid Control and Risk of Flare According to Different Cut-Offs in Patients with Gout: Longitudinal Analysis From the King Study of the Italian Society for Rheumatology

Post-Marketing Safety Surveillance Data Reveals Patterns of Use for Pegloticase in Refractory Chronic Gout

Improvements in Long-Term Health-Related Quality of Life in Chronic Gout Patients Refractory to Conventional Therapies Treated with Pegloticase: Results From Responder Cohort

Towards a Preliminary Definition of Remission From Gout

Natural Language Processing in the Evaluation of Gout Quality Indicators

Simple Search Results